Epidemiologic review of the calcium channel blocker drugs. An up-to-date perspective on the proposed hazards

Archives of Internal Medicine
J R Kizer, S E Kimmel

Abstract

In the setting of soaring popularity, postmarketing studies of calcium channel blockers came to suggest an increase in a variety of major adverse end points. The evidence, however, was largely observational, and large-scale trials capable of addressing the concerns were wanting. Clinical trials now support the safety and efficacy of the long-acting dihydropyridines for patients with both uncomplicated and diabetic hypertension, although conventional therapies and, in the latter case, angiotensin-converting enzyme inhibitors have superior proof of benefit. By contrast, short-acting dihydropyridines should be avoided. In the acute coronary syndromes, beta-blockers remain the treatment of choice; the evidence for nondihydropyridines remains inconclusive. Stable angina calls for beta-blockers as first-line therapy and nondihydropyridines as second-line therapy, whereas in ventricular dysfunction, safety data for nondihydropyridines are lacking. Initial reports of cancer, bleeding, and suicide have been contradicted by subsequent data, making the associations uncertain or unlikely. Remaining questions await completion of ongoing trials to better define the indications for these agents.

Citations

Aug 19, 2011·The Journal of Pharmacology and Experimental Therapeutics·Marcus M Reidenberg
Jun 23, 2006·Breast Cancer Research and Treatment·Jon P FryzekSøren Friis
Apr 20, 2004·Assay and Drug Development Technologies·David J Triggle
Nov 13, 2004·The Journal of Clinical Hypertension·Jan Basile
Jun 27, 2003·The Journal of Clinical Hypertension·George L BakrisUNKNOWN Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators
Jan 5, 2002·Diabetes Care·Carlos Arauz-PachecoPhilip Raskin
Mar 6, 2004·The Journal of Thoracic and Cardiovascular Surgery·Duminda N WijeysunderaKeyvan Karkouti
Nov 13, 2004·Medical Care Research and Review : MCRR·Julia S HolmesDavid Share
Apr 25, 2003·American Journal of Medical Quality : the Official Journal of the American College of Medical Quality·Patricia GladowskiSanford Reich
Nov 19, 2003·American Journal of Therapeutics·Zafar H Israili
Nov 8, 2007·Research in Sports Medicine·Poul-Erik Paulev, Gustavo Zubieta-Calleja
Feb 28, 2009·Journal of the Cardiometabolic Syndrome·Icilma V Fergus
Oct 24, 2007·Drugs & Aging·Blayne K Welk, Joel M H Teichman
Nov 16, 2010·Journal of Internal Medicine·I S MackenzieL Wei
Mar 23, 2006·Cardiovascular Drugs and Therapy·Philip A Poole-WilsonUNKNOWN ACTION Investigators
Apr 11, 2012·International Journal of Cancer. Journal International Du Cancer·Chenming MaWolfgang Kemmner
May 3, 2012·The Neurologist·Suber DikiciAbdulkadir Kocer
May 20, 2009·Journal of Hypertension·Pierluigi CostanzoMassimo Chiariello
Sep 6, 2007·The Journal of Clinical Hypertension·Domenic A Sica, Rosemarie Mannino
Sep 2, 2011·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Robert F ReynoldsSybil M Eng
Sep 22, 2001·Hospital Practice·M R Weir
Jun 13, 2003·Blood Pressure. Supplement·Claudio BorghiUNKNOWN Study Group of the Regional Unit of the Italian Society of Hypertension
May 16, 2020·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jin WangLingzhong Meng
Oct 4, 2003·Drugs·Paul L McCormack, Antona J Wagstaff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.